Company Performance Metrics
Bionovo, Inc. operates as a late stage clinical drug discovery and development company focusing on women’s health and cancer primarily in the United States. The company’s drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds. Its lead drug candidate is Menerba, a receptor
sub-type selective estrogen receptor modulator, which is in Phase III clinical trial for the treatment of vasomotor symptoms of menopause. The company is also developing Bezielle, an oral anti-cancer agent that in Phase II clinical trail for the treatment of advanced breast cancer; and Seala for the treatment of post-menopausal vulvar and vaginal atrophy. Bionovo, Inc. was founded in 2002 and is headquartered in Emeryville, California. On October 26, 2012, Bionovo, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.
